on June 15, 2006
Published online before print June 15, 2006, doi: 10.1161/01.ATV.0000232542.42968.e3
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on November 3, 2005
Accepted on June 2, 2006
Transcriptional Regulators of Angiogenesis
Anne Hamik ;
From the Program in Cardiovascular Transcriptional Biology, Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass.
* To whom correspondence should be addressed. E-mail: mjain{at}rics.bwh.harvard.edu.
Abstract--Angiogenesis, the process by which new blood vessels develop from a pre-existing vascular network, is essential for normal development and in certain physiological states. Inadequate or excessive angiogenesis has been incriminated in a number of pathologic states. For example, vaso-occlusive disease arising from atherosclerosis can lead to ischemia, a situation in which enhanced angiogenesis would be beneficial. Conversely, overzealous angiogenesis can contribute to tumor development and in this case inhibition of angiogenesis is desirable. Thus, strategies to induce or inhibit angiogenesis are of considerable therapeutic interest.
This article has been cited by other articles:
 |
|
 |
|
  J. Niu, A. Azfer, O. Zhelyabovska, S. Fatma, and P. E. Kolattukudy Monocyte Chemotactic Protein (MCP)-1 Promotes Angiogenesis via a Novel Transcription Factor, MCP-1-induced Protein (MCPIP) J. Biol. Chem., May 23, 2008; 283(21): 14542 - 14551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Doyle and N. Caplice Plaque Neovascularization and Antiangiogenic Therapy for Atherosclerosis J. Am. Coll. Cardiol., May 29, 2007; 49(21): 2073 - 2080. [Abstract] [Full Text] [PDF]
|
|